FDA reviewers question efficacy of Pfizer's kidney cancer drug ahead of ODAC
This article was originally published in Scrip
Executive Summary
AVEO Pharmaceuticals got a 4.6% boost by investors on 5 December when the US FDA questioned the efficacy of potential competitor Pfizer's experimental advanced renal cell carcinoma drug (RCC) Inlyta (axitinib), an oral tyrosine kinase inhibitor (TKI).